Approach to Critical Quality Attributes (CQA) Designation of Lipid Nanoparticles Enabling Gene Therapies

Keeth Jain is an Associate Director within the MS&T group at Generation Bio, Cambridge MA. In his current role, he is responsible for CMC development and manufacturing of innovative cell-targeted lipid nanoparticles-based drug product to create a new class of gene therapy utilizing a proprietary non-viral platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. Prior to joining Generation Bio in 2021, Keeth worked at Shire and Takeda assuming different roles and was responsible for drug product development of multiple products across different modalities. Keeth earned his MS in Pharmaceutical Sciences from Northeastern University, Boston, MA.